Why Wall Street Wasn't Bothered by Jazz Pharmaceuticals' Mixed Q4 Results

Why Wall Street Wasn't Bothered by Jazz Pharmaceuticals' Mixed Q4 Results

The biggest news for Jazz Pharmaceuticals (NASDAQ: JAZZ) in recent months was the company's announcement earlier this month that it plans to acquire GW Pharmaceuticals in a $7.6 billion deal. Now, Jazz has more news that investors eagerly awaited. Here are the highlights from Jazz's Q4 update.